Swiss National Bank’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.57M Hold
16,300
﹤0.01% 1969
2025
Q4
$1.59M Buy
16,300
+500
+3% +$42.9K ﹤0.01% 1974
2025
Q3
$1.12M Hold
15,800
﹤0.01% 2116
2025
Q2
$945K Buy
15,800
+800
+5% +$43.8K ﹤0.01% 2168
2025
Q1
$787K Hold
15,000
﹤0.01% 2235
2024
Q4
$825K Hold
15,000
﹤0.01% 2288
2024
Q3
$754K Hold
15,000
﹤0.01% 2328
2024
Q2
$659K Sell
15,000
-1,200
-7% -$51K ﹤0.01% 2349
2024
Q1
$713K Buy
16,200
+1,300
+9% +$57.5K ﹤0.01% 2369
2023
Q4
$707K Sell
14,900
-1,700
-10% -$71.5K ﹤0.01% 2402
2023
Q3
$737K Buy
+16,600
New +$771K ﹤0.01% 2395

Other funds holding IRMD

Swiss National Bank's IRMD Position: Q1 2026 in Review

Swiss National Bank held its iRadimed (IRMD) position steady in Q1 2026 at 16,300 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #1969.

Swiss National Bank first reported a position in IRMD in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.59M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • Swiss National Bank held 16,300 shares of iRadimed worth $1.57M as of Q1 2026.
  • Swiss National Bank left its iRadimed share count unchanged in Q1 2026.
  • iRadimed made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #1969 holding.
  • Swiss National Bank first reported a position in iRadimed in Q3 2023 and has held it in 11 quarters since.
  • Swiss National Bank's iRadimed position peaked at $1.59M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.